Opthea (FRA:UKJ) Current Accrued Expense : €23.53 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Opthea Current Accrued Expense?

Opthea's Current Accrued Expense for the quarter that ended in Dec. 2024 was €23.53 Mil.

Opthea's quarterly Current Accrued Expense stayed the same from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€0.00 Mil) but then increased from Jun. 2024 (€0.00 Mil) to Dec. 2024 (€23.53 Mil).

Opthea Current Accrued Expense Historical Data

The historical data trend for Opthea's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Current Accrued Expense Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Current Accrued Expense

Get a 7-Day Free Trial

Opthea Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	23.53

Opthea Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Opthea Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Opthea's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

OPT:USA OPT:Australia

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Opthea Headlines

No Headlines